In a phase II clinical trial of hu14.18-IL2, complete resolution of bone marrow disease and metaiodobenzylguanidine avid disease was seen in 5 out of 24 Stratum-2 patients with relapsed-refractory neuroblastoma (175). Here, IL2 is linked to neuroblastoma.